Bronchogen

Bronchogen — Bronchial / Lung Bioregulator

Bronchogen is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in bronchial / lung tissue.

Peptide Specifications

Parameter	Value
Sequence	Ala-Glu-Asp-Leu
Mass	432.4 g/mol
Purity	>98.0%
Target Organ	Bronchial / Lung

Figure 1: Bronchogen Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Targets bronchial epithelial cells with tissue-specific gene regulation.
2. Restores ciliary beat frequency and mucociliary clearance.
3. Normalizes mucus-to-serous secretion ratio.
4. Reduces chronic inflammatory infiltration in bronchial submucosa.
5. Promotes Type II alveolar cell regeneration.

Figure 2: Bronchial / Lung Regeneration Curve

Research Results

• 1: Restores chronic respiratory tissue degradation from COPD.
• 2: Normalizes pulmonary function test values.
• 3: Deep tissue-level regeneration beyond bronchodilators.

Respiratory Tissue Bioregulator

Bronchogen (Ala-Glu-Asp) is a synthetic tripeptide bioregulator derived from bronchial and lung tissue extracts, targeting respiratory epithelial and smooth muscle cell gene expression. The respiratory epithelium undergoes significant age-related changes: ciliary beat frequency decreases, mucus composition shifts toward more viscous profiles, surfactant production declines, and the mucociliary clearance system becomes less efficient. Bronchogen restores the transcriptional programs governing these functions, supporting age-appropriate respiratory defense and gas exchange efficiency.

1. Bronchogen modulates chromatin accessibility in respiratory epithelial cells at promoter regions controlling ciliary dynein expression and ciliary beat frequency.
2. Mucin gene expression (MUC5AC, MUC5B) is normalized, restoring optimal mucus rheology for effective mucociliary transport.
3. Type II pneumocyte surfactant protein expression (SP-A, SP-B, SP-C, SP-D) is upregulated, maintaining alveolar surface tension reduction and innate immune defense.
4. Airway smooth muscle contractile gene expression is normalized, reducing age-related airway hyperresponsiveness.
5. Antioxidant defense in the airway lining fluid (glutathione, SOD) is restored, protecting against oxidative damage from inhaled pollutants.

Pulmonary Research Applications

• COPD Research: In chronic bronchitis models, Bronchogen course administration improved mucociliary clearance rates and reduced inflammatory cell counts in bronchoalveolar lavage.
• Aging Lung: Age-related decline in FEV1 (approximately 25–30 mL/year after age 35) may be attenuated by restoring surfactant and mucociliary function.
• Post-Infection: After respiratory infections, Bronchogen supports recovery of normal epithelial function and ciliary activity damaged by viral cytopathic effects.
• Combination: Often paired with Chonluten (bronchial mucosa bioregulator) for comprehensive respiratory bioregulator protocols.
• Protocol: 1–2 capsules daily for 20–30 days. Seasonal administration (autumn, spring) aligns with periods of increased respiratory challenge.